Aquilo Capital Management, LLC Genmab A/S Transaction History

Aquilo Capital Management, LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	SELL	$35.27 - $42.24 $4.32 Million - $5.17 Million	-122,500 Reduced 70.14%	52,148 $1.84 Million
Q2 2023 Aug 14, 2023	SELL	$37.4 - $42.94 $2.55 Million - $2.93 Million	-68,200 Reduced 28.08%	174,648 $6.64 Million
Q4 2022 Feb 14, 2023	SELL	$33.8 - $47.06 $67,600 - $94,120	-2,000 Reduced 0.82%	242,848 $10.3 Million
Q3 2022 Nov 14, 2022	BUY	$31.52 - $373.61 $945,600 - $11.2 Million	30,000 Added 13.96%	244,848 $7.87 Million
Q2 2022 Aug 15, 2022	BUY	$26.83 - $38.57 $1.27 Million - $1.83 Million	47,348 Added 28.27%	214,848 $6.98 Million
Q1 2022 May 16, 2022	BUY	$30.95 - $39.68 $1.24 Million - $1.59 Million	40,000 Added 31.37%	167,500 $6.06 Million
Q3 2021 Nov 15, 2021	BUY	$41.55 - $48.72 $311,625 - $365,400	7,500 Added 6.25%	127,500 $5.57 Million
Q1 2021 May 17, 2021	BUY	$30.92 - $44.4 $927,600 - $1.33 Million	30,000 Added 33.33%	120,000 $3.94 Million
Q4 2020 Feb 16, 2021	BUY	$33.66 - $40.76 $1.35 Million - $1.63 Million	40,000 Added 80.0%	90,000 $3.66 Million
Q3 2020 Nov 16, 2020	BUY	$33.07 - $38.68 $1.65 Million - $1.93 Million	50,000 New	50,000 $1.83 Million

240

52.6M

10.2K

25.5K

Ticker GMAB
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 658,292,992
Market Cap $14.6B
Description
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphoc...

Get notified when there are updates to the investment portfolio of Aquilo Capital Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Aquilo Capital Management, LLC with notifications on news.